Когнитивные нарушения при сердечно-сосудистых заболеваниях, ассоциированных с атеросклерозом. Возможности коррекции ницерголином (Сермионом)
Аннотация
В статье представлен обзор литературы проблеме когнитивных нарушений при сердечно-сосудистых заболеваниях, ассоциированных с атеросклерозом. Авторы представили анализ литературных данных о факторах, влияющих на формирование когнитивных нарушений, частоте их развития. В статье представлены современные аспекты патогенеза когнитивных нарушений при сердечно-сосудистых заболеваниях, ассоциированных с атеросклерозом, а также обсуждается вклад представленных факторов риска в их развитие. Особое внимание уделено вопросам терапии когнитивных нарушений препаратом, обладающим высокой степенью сродства к а1-адренорецепторам - ницерголину (Сермиону). Обсуждаются вопросы назначения данного препарата при различных видах и степени выраженности когнитивных нарушений, а также представлен обзор литературных данных по эффективности и безопасности его применения.
Об авторах
О. А. Трубникова
ФГБУН «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Министерства науки и высшего образования России
Россия
Россия
О. Л. Барбараш
ФГБУН «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Министерства науки и высшего образования России
Россия
Россия
Т. В. Куприянова
ГБУЗ КО «Кемеровский областной клинический кардиологический диспансер имени академика Л.С. Барбараша»
Россия
Россия
Список литературы
1. Prince M., Wimo A., Guerchet M., et al. World Alzheimer report 2015. The global impact of dementia. An Analysis of Prevalence, Incidence, Cost and Trends 2015. https://www.alz.co.uk/research/WorldAlz-heimerReport2015.pdf.
2. Yang M., Guo Y., Gong J. et al. Relationships between functional fitness and cognitive impairment in Chinese community-dwelling older adults: a cross-sectional study. // BMJ. - 2018. - Vol. 20. - № 8 (5): e 020695.
3. Global, regional, and national disability-adjusted life-years (DALYs) for333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. // Lancet. - 2017. - Vol. 390 (10100) - P. 1260-1344.
4. Измеров Н.Ф., Тихонова Г.И., Горчакова Т.Ю. Смертность населения трудоспособного возраста в России и развитых странах Европы: тенденции последнего двадцатилетия. // Вестн. РАМН. - 2014. - Т. 69 (7-8). - С. 121-126.
5. Justin B.N., Turek M., Hakim A. M. Heart disease as a risk factor for dementia. // Nat. Rev. Neurol. - 2015. - Vol. 11 (11). - P. 651657.
6. Debette S., Markus H.S. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. // BMJ. - 2010; 341: c3666.
7. Еремина Д.А. Динамика когнитивных функций больных ишемической болезнью сердца в процессе реабилитации после коронарного шунтирования: автореф. дис.. канд. психолог. наук / Д.А. Еремина. - СПб. 2015. - 24 с.
8. Литвиненко М.А., Котов А.С., Романов С.В. и др. Нейрокогнитивный скрининг у пациентов с ишемической болезнью сердца, нуждающихся в хирургическом лечении. // Альманах клинической медицины. - 2015. - № 39. - С. 51-55.
9. Schievink S.H.J., van Boxtel M.P.J., Deckers K. et al. Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the Maastricht Aging Study (MAAS). // Eur. Heart J. - 2017. - Jul 22. doi: 10.1093/eurheartj/ehx365. [Epub ahead of print].
10. Waldstein S.R., Brown J.R., Maier K.J. et al. Diagnosis of hypertension and high blood pressure levels negatively affect cognitive function in older adults. // Ann. Behav. Med. - 2005. - Vol. 29 (3). - P. 174-180.
11. Armstrong J.J., Mitnitski A., Launer L.J. et al. Frailty in the Honolulu-Asia aging study: deficit accumulation in a male cohort followed to 90% mortality. // J. Gerontology. Series A: Biomedical Sciences and Medical Sciences. - 2014. - Vol. 70 (1). - P. 125-131.
12. Satizabal C.L., Beiser A.S., Chouraki V. et al. Incidence of dementia over three decades in the Framingham Heart Study. // New England J. Med. - 2016. - Vol. 374 (6). - P. 523-532.
13. Alonso A., Knopman D.S., Gottesman R.F. et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). // J. Am. Heart Assoc. - 2017. - Vol. 6 (7): e006014.
14. Novak V., Hajjar I. The relationship between blood pressure and cognitive function. // Nat. Rev. Cardiol. - 2010. - Vol. 7 (12). - P. 686-698.
15. Cherbuin N., Reglade-Meslin C., Kumar R. et al. Risk factors of transition from normal cognition to mild cognitive disorder: the PATH through Life Study. // Dement. Geriatr. Cogn. Disord. - 2009. - Vol. 28 (1). - P. 47-55.
16. Peters R., Beckett N., Forette F. et al. Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. // Int. Psychogeriatr. - 2009. - Vol. 21 (2). - P. 359-368.
17. Коваленко Е.А., Махнович Е.В., Боголепова А.Н. Роль артериального давления в формировании когнитивных нарушений. // Медицинский алфавит. - 2016. - Т. 1. - № 31. - С. 11-14.
18. Левин О. С. Когнитивные нарушения в практике терапевта: заболевания сердечно-сосудистой системы. // Consilium medicum. - 2009. - Т. 11. - № 2. - С. 55-61.
19. Hoffman L.B., Schmeidler J., Lesser G.T., et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. // Neurology. - 2009. Vol. 72 (20). P. 1720-1726.
20. Захаров В.В. Когнитивные нарушения при артериальной гипертензии. // Нервные болезни. - 2013. - № 3. - С. 16-21.
21. Левин О. С. Патология белого вещества при дисциркуляторной энцефалопатии: диагностические и терапевтические аспекты. // Труд. пациент. - 2011. - № 12. - С. 16-24.
22. Harkness K., Demers C. Screening for cognitive deficits using the Montreal cognitive assessment tool in outpatients > 65 years of age with heart failure. // Am. J. Cardiol. - 2011. - Vol. 107. - P. 1203-1207.
23. Alagiakrishnan K., Mah D., Ahmed A. et al. Cognitive decline in heart failure. // Heart failure reviews. - 2016. - Vol. 21 (6). - P. 661-673.
24. Femminella G. D., Candido C., Conte M. et al. Cognitive Function and Heart Failure: The Role of the Adrenergic System. // Recent Pat Endocr. Metab. Immune Drug Discov. - 2016. - Vol. 10 (1). - P. 40-49.
25. Haeusler K.G., Laufs U., Endres M. Chronic heart failure and ischemic stroke. // Stroke. - 2011. - Vol. 42 (10). - Р. 2977-2982.
26. Pullicino P.M., McClure L.A., Howard V.J. et al. Identifying a high stroke risk subgroup in individuals with heart failure. // J. Stroke and Cerebrovascular Diseases. - 2013. - Vol. 22 (5). - P. 620-626.
27. Hwang, S.Y., Kim J.S. An examination of the association of cognitive functioning, adherence to sodium restriction and Na/K ratios in Korean heart failure patients. // J. Clin. Nursing. - 2016. - Vol. 25 (11-12). - P. 1766-1776.
28. Howell E.H., Senapati A., Hsich E. et al. Medication self-management skills and cognitive impairment in older adults hospitalized for heart failure: A cross-sectional study. // SAGE Open Med. - 2017. - Vol. 23 (5): 2050312117700301. doi: 10.1177/2050312117700301. eCollection 2017.
29. Jefferson A.L., Himali J.J., Beiser A.S., et al. Cardiac index is associated with brain aging: the Framingham Heart Study. // Circulation. - 2010 - Vol. 122 (7). - P. 690-697.
30. Stanek K.M., Gunstad J., Paul R. H., et al. Longitudinal cognitive performance in older adults with cardiovascular disease: evidence for improvement in heart failure. // J Cardiovasc Nurs. - 2009. - Vol. 24 (3). - P. 192-197.
31. Woltz P. Health-related Quality of Life and Mortality in Incident Heart Failure from the Cardiovascular Health Study (CHS). // University of Maryland, Baltimore, 2014. https://pqdtopen.proquest.com/doc/1548329261.html?FMT=AI.
32. Cohen M. B., Mather P. J. A review of the association between congestive heart failure and cognitive impairment. // Am. J. Geriatr. Cardiol. - 2007. - Vol. 16 (3). - P. 171-174.
33. Cannon J. A., Moffitt P., Perez-Moreno A.C. et al. Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. // J. Card. Fail. - 2017. - Vol. 23 (6). - P. 464-475.
34. Боголепова А.Н. Проблемы медикаментозной терапии больных с когнитивными нарушениями. // Consilium Medicum. - 2012. - Т. 14. - № 2. - С. 27-31.
35. Almeida O.P., Garrido G.J., Etherton-Beer C. et al. Brain and mood changes over 2 years in healthy controls and adults with heart failure and ischaemic heart disease. // Eur. J. Heart Fail. - 2013. - Vol. 15 (8). - Р. 850-858.
36. Halling A., Berglund J. Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. // Eur. J. Gen. Pract. - 2006. - Vol. 12 (3). - P. 114-119.
37. Sierra S., Ramos M. C., Molina P. et al. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. // J. Alzheimers. Dis. - 2011. - Vol. 23. - P. 307-318.
38. Melinda C. Power, Weuve J., Sharrett R. et al. Gottesman. Statins, cognition, and dementia-systematic review and methodological commentary. //Nat. Rev. Neurol. - 2015. - Vol. 11 (4). - P. 220-229.
39. Lin Q., Huang W.Q., Ma Q.L. et al. Incidence and risk factors of leukoaraiosis from 4683 hospitalized patients: a cross-sectional study. // Medicine. 2017; 96 (39): e7682.
40. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? // Exp Gerontol. - 2011. Vol. 146 (4). - P. 225-232.
41. Farr S. A., Yamada K. A., Butterfield D. A. et al. Obesity and hypertriglyceridemia produce cognitive impairment. // Endocrinol. - 2008. - Vol. 149 (5). - P. 2628-2636.
42. Деревнина Е.С., Акимова Н.С., Мартынович Т.В. и др. Когнитивные нарушения при фибрилляции предсердий на фоне сердечно-сосудистых заболеваний. // Анналы аритмологии. - 2013. - Т. 10. - № 2. - С. 87-94.
43. Hui D. S., Morley J. E., Mikolajczak P. C. et al. Atrial fibrillation: a major risk factor for cognitive decline. / Am. Heart J. - 2015. - Vol. 169 (4). - P. 448-456.
44. Gaita F., Corsinovi L., Anselmino M. et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. // J. Am. Col. Cardiol. - 2013. - Vol. 62 (21). - P. 1990-1997.
45. Chen L.Y., Lopez F.L., Gottesman R.F. et al. Atrial fibrillation and cognitive decline - the role of subclinical cerebral infarcts. // Stroke. - 2014. - Vol. 45 (9). - P. 2568-2574.
46. Thacker E.L., McKnight B., Psaty B.M. et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. // Neurology. - 2013. - Vol. 81 (2). - P. 119-125.
47. Kalantarian S., Ruskin J. N. Atrial fibrillation and cognitive. // Cardiology clinics. - 2016. - Vol. 34 (2). - P. 279-285.
48. Puccio D., Novo G., Baiamonte V. et al. Atrial fibrillation and mild cognitive impairment: what correlation? // Minerva Cardioangiol. - 2009. - Vol. 57 (2). - P. 143-150.
49. Hotta R., Shimada H., Makizako H. et al. Cigarette smoking and cognitive health in elderly Japanese. // Am. J. Health Be-havior. - 2015. - Vol. 39 (3). - P. 294-300.
50. Mons U., Schöttker B., Müller H. et al. History of lifetime smoking, smoking cessation and cognitive function in the elderly population. // Eur. J. Epidemiol. - 2013. - Vol. 28, Issue 10. - Р. 823-831.
51. Majdi A., Kamari F., Vafaee M. S. et al. Revisiting nicotine's role in the ageing brain and cognitive impairment. // Rev Neurosci. - 2017. - Vol. 28 (7). - P. 767-781.
52. Demars M.P., Morishita H. Cortical parvalbumin and somatostatin GABA neurons express distinct endogenous modulators of nicotinic acetylcholine receptors. // Cortical Molecular Brain. - 2014. - Vol. 7. - P. 75-79.
53. Vangkilde S., Bundesen C., Coull J. T. Prompt but inefficient: nicotine differentially modulates discrete components of attention. // Psychopharmacology. - 2011. - Vol. 218 (4). - P. 667-680.
54. Chamberlain S. R., Odlaug B. L., Schreiber L. R.N. et al. Association between tobacco smoking and cognitive functioning in young adults. // Am. J. Addictions. - 2012. - Vol. 21. - S. 14-19.
55. Barnes D.E., Haight T.J., Mehta K.M. et al. Secondhand smoke, vascular disease, and dementia incidence: findings from the cardiovascular health cognition study. // Am.J. Epidemiol. - 2010. - Vol. 171 (3). - P. 292-302.
56. Kaarin J. Anstey Chwee von Sanden Agus Salim Richard O'Kearney. Smoking as a Risk Factor for Dementia and Cognitive Decline: A Meta-Analysis of Prospective Studies. // Am. J. Epidemiology. - 2007. - Vol. 166 (4). - P. 367-378.
57. Rundek T., Della-Morte D., Gardener H. et al. Relationship between carotid arterial properties and cerebral white matter hyperintensities. // Neurology. - 2017. - Vol. 88 (21). - P. 2036-2042.
58. Moroni F., Ammirati E., Rocca M.A. et al. Cardiovascular disease and brain health: Focus on white matter hyperintensities. // Int J Cardiol Heart Vasc. - 2018. - Vol. 19. - P. 63-69.
59. Markus H.S., King A., Shipley M. et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. // Lancet Neurol. - 2010. - Vol. 9 (7). - P. 663-671.
60. Mathiesen E. B., Waterloo K., Joakimsen O. et al. Reduced neuropsychological test performance in asymptomatic carotid stenosis: The Tromso Study. // Neurology. - 2004. - Vol. 62 (5). - P. 695-701.
61. Trubnikova О.А., Tarasova I.V., Barbarash O.L. Impact of low and moderate carotid stenoses on neurophysiological status of patients undergoing on-pump coronary artery bypass grafting. // Frontiers in Neurology. - 2012. - Vol. 3. - Р. 1-5.
62. Cukierman-Yaffe T., Gerstein H. C., Williamson J. D. et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. // Diabetes Care. - 2009. - Vol. 32(2). - P. 221-226.
63. Van den Berg E., Kessels R. P., Kappelle L. J. et al. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. // Drugs Today (Barc). - 2006. - Vol. 42 (11). - P. 741-754.
64. Laron I. Insulin and the brain. // Arch. Physiol. Biochem. - 2009. - Vol. 115. - P. 112-116.
65. Emmanuel Y., Cochlin L.E., Tyler D. J. et al. Human hippocampal energy metabolism is impaired during cognitive activity in a lipid infusion model of insulin resistance. / / Brain Behav. - 2013. - Vol. 3 (2). - P. 134-144.
66. Williamson R., McNeilly A., Sutherland C. Insulin resistance in the brain: an old-age or new-age problem? // Biochem. Pharmacol. - 2012. - Vol. 84 (6). - P. 737-745.
67. Jacobson A.M., Musen G., Ryan C. M. et al. Long-term effect of diabetes and its treatment on cognitive function. // N. Engl. J. Med. - 2007. - Vol. 356 (18). - P. 184-1852.
68. Gannon M. Che P., Chen Y. et al. Noradrenergic dysfunction in Alzheimer's disease. // Front. Neurosci. - 2015. - V. 9 (220). - Р. 1-12.
69. Fitzgerald P.J. Noradrenaline transmission reducing drugs may protect against a broad range of diseases. // Auton. Autacoid Pharmacol. - 2015. - Vol. 34 (3-4). - P. 15-26.
70. Kozisek M.E., Bylund D.B. Norepinephrine/ Epinephrine. // Handbook of Contemporary Neuropharmacology. Hoboken, NJ, USA: John Wiley & Sons, Inc., 200.
71. West A.E., Greenberg M.E. Neuronal activity-regulated gene transcription in synapse development and cognitive function. // Cold Spring Harbor Perspectives in Biology. - 2011. - Vol. 3 (6). doi:10.1101/cshperspect.a005744.
72. Smith E.E., Greenberg S.M. Beta-amyloid, blood vessels, and brain function. // Stroke. - 2009. - Vol. 40 (7). - P. 2601-2606.
73. Price J.M., Sutton E.T., Hellermann A., Thomas T. beta-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res. 1997; 19: 534-538.
74. Gentile M.T., Vecchione C., Maffei A., Aretini A., Marino G., Poulet R., Capobianco L., Selvetella G., Lembo G. Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem. 2004; 279: 48135-48142. doi: 10.1074/jbc.M407358200.
75. Wenzel K., Haase H., Wallukat G. et al. Potential functional relevance of a1-adrenergic receptor autoantibodies in refractory hypertension. // PLoS One. - 2008. - Vol. 3. - e3742.
76. Zhou C.C., Zhang Y., Irani R. et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. // Nat Med. - 2008. - Vol. 14. - P. 855-62.
77. Karczewski P., Pohlmann A., Wagenhaus B. et al. Antibodies tothe alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. // PLoS One. - 2012; 7 (7): e4 1602. doi:10.1371/journal.pone.0041602.
78. Pohlmann A., Karczewski P., Ku M.C. et al. Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of a1-adrenergic receptor antibodies. // NMR Biomed. - 2014. - Vol. 27. - P. 1085-93.
79. Liao Y.H., Wei Y.M., Wang M. et al. Autoantibodies against AT1-receptor and a1-adrenergic receptor in patients with hypertension. // Hypertens Res. - 2002. - Vol. 25 (6). - P. 41-646.
80. René Thyrian J., Hertel J., N Schulze L., et al. Prevalence and Determinants of Agonistic Autoantibodies Against a1-Adrenergic Receptors in Patients Screened Positive for Dementia: Results from the Population-Based DelpHi-Study. // J Alzheimers Dis. - 2018. Jun 27. doi: 10.3233/JAD-171096. [Epub ahead of print].
81. Karczewski P., Hempel P., Kunze R., Bimmler M. Agonistic Autoantibodies to the a1-Adrenergic Receptor and the ß2-Adrenergic Receptor in Alzheimer's and Vascular Dementia. // Scand. J. Immunol. - 2012. - Vol. 75 (5). - P. 524-530.
82. Hempel P., Heinig B., Jerosch C. et al. Immunoadsorption of Agonistic Autoantibodies Against a1-Adrenergic Receptors in Patients With Mild to Moderate Dementia. // Ther Apher Dial. - 2016. - Vol. 20 (5). - P. 523-529.
83. Ezan E., Delestre L., Legendre S. et al. Immunoassays for the detection of nicer-goline and its metabolites in human plasma. // Journal of Pharmaceutical and Biomedical Analysis. - 2001. - Vol. 25 (1). - P. 123-130.
84. Winblad B., Fioravanti M., Dolezal T. et al. Therapeutic use of nicergoline. // Clinical Drug Investigation. - 2008. - Vol. 28 (9). - P. 533-552.
85. Atri A. Effective pharmacological management of Alzheimer's disease. // The American Journal of Managed Care. - 2011. - Vol. 17 (13). - S 346-S 355.
86. Sortino M.A., Battaglia A., Pamparana F. et al. Neuroprotective effects of nicergoline in immortalized neurons. // European Journal of Pharmacology. - 1999. - Vol. 368 (2-3). - P. 285-290.
87. Carfagna N., Rossi A. Nicergoline: biochemical studies on neuronal metabolism. // Functional Neurology. - 1989. - Vol. 4 (4). - P. 177-185.
88. Fioravanti M., Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. // Cochrane Database Syst Rev. - 2001. - (4): CD 003159.
89. Giardino L., Giuliani A., Battaglia A. et al. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion). // Neuroscience. - 2002. - Vol. 109 (3). - P. 487-497.
90. Caraci F., Chisari M., Frasca G. et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. // Brain Res. - 2005. - Vol. 1047 (1). - P. 30-37.
91. Zang G., Fang L., Chen L., Wang C. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease. // Mol Med Rep. - 2018. - Vol. 17(5). - P. 293-7300.
92. Fioravanti M., Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. // Cochrane Database of Systematic Reviews. - 2001. - (4): CD 003159.
93. Markesbery W.R. Neuropathologic alterations in mild cognitive impairment: a review. // Journal of Alzheimer's Disease. - 2010. - Vol. 19 (1). - P. 221-228.
94. Boulu P. Effects du Sermion sur les troubles mnesiques et les fonctions de la vie de relation. Analyse d'une population de 1 o 488 patients, a terrain vasculaire, suivis pendant 6 mo'is. // Tempo medical. - 1990; 397: 24-27.
95. Saletu B., Garg A., Shoeb A. Safety of nicergoline as an agent for management of cognitive function disorders. // Biomed Res Int. - 2014: 610103. DOI: 10,1155 /2014/610103.
96. Nicergoline Cooperative Study Group (1990). A double-blind randomised study of two ergot-derivatives in mild to moderate dementia. // Current Therapeutic Research. - 1990, 48: 597-612.
97. Kugler J.E., Meurer-Krull B.C. Electroencephalographic and psychometric measurements during treatment of cerebral insufficiency with nicergoline and dihydroergot-aminemesilate. // Arzneimittel-Forschung. - 1985. - Vol. 35 (12). - P. 1865-1870.
98. Battaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. // Journal of the American Geriatrics Society. - 1989. - Vol. 37 (4). - P. 295-302.
99. Tomcsanyi J., Vecsey T., Tâtrai T. Nicergoline - induced Prinzmetal angina. ‘Heartache’ instead of headache. Orvosi Hetilap. - 2004. - Vol. 145 (1). - P. 31-32.
100. Felisati G., Battaglia A., Papini M. G. et al. Nicergoline in balance alterations in adult and elderly patients: a double-blind, placebo-controlled study. // Clinical Drug Investigation. - 2002. - Vol. 22 (11). - P. 731-740.
101. Boismare F., Lefrancois J. Haemodynamic effects of nicergoline in man at rest and during exercise. // Clinical and Experimental Pharmacology and Physiology. - 1980. - Vol. 7 (2). - P. 105-112.
102. Bès A., Orgogozo J., Poncet M., et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. // European Journal of Neurology. - 1999. - Vol. 6 (3). - P. 313-322.
103. Saletu B., Paulus E., Linzmayer L. et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double blind, placebo controlled, clinical and EEG/ERP mapping study. // Psychopharmacology. - 1995. - Vol. 117 (4). - P. 385-395.
104. Herrmann W. M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. // Dementia and Geriatric Cognitive Disorders. - 1997. - Vol. 8 (1). - P. 9-17.
105. European Medicines Agency [Internet]. [cited 2018 Jul 27]. New restrictions on use ofmedicines containing ergot derivatives. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001832.jsp&mid=WC 0b01ac058004d5c1b.
106. Fioravanti M., Nakashima T., Xu J., Garg A.A systematic review and meta-analysis assessing adverse event profile and tol-erability of nicergoline. // BMJ. - 2014. - Vol. 4. (7): e005090. doi: 10.1136/bmjopen-2014-005090.
Рецензия
Для цитирования:
Трубникова О.А., Барбараш О.Л., Куприянова Т.В. Когнитивные нарушения при сердечно-сосудистых заболеваниях, ассоциированных с атеросклерозом. Возможности коррекции ницерголином (Сермионом). Медицинский алфавит. 2018;2(21):20-28.
For citation:
Trubnikova O.A., Kupriyanova T.V., Barbarash O.L. Cognitive impairment in cardiovascular diseases associated with atherosclerosis. Possibilities of its correction with nicergoline (Sermion). Medical alphabet. 2018;2(21):20-28. (In Russ.)
Просмотров:
375
Послать статью по эл. почте 